Craft

Allergy Therapeutics

Stock Price

£0.1

2024-10-29

Market Capitalization

£252.6 M

2024-10-29

Revenue

£55 M

FY, 2025

Allergy Therapeutics Summary

Company Summary

Overview
We provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.
Type
Public
Status
Active
Founded
1934
HQ
Worthing, GB | view all locations
Website
http://www.allergytherapeutics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Peter Jensen

    Peter Jensen, Non-Executive Chairman

    • Stephen Smith

      Stephen Smith, Non-Executive Director

      • Tunde Otulana

        Tunde Otulana, Non-Executive Director

        • Manuel Llobet

          Manuel Llobet, Chief Executive Officer

          LocationsView all

          1 location detected

          • Worthing, England HQ

            United Kingdom

            Dominion Way

          Allergy Therapeutics Financials

          Summary Financials

          Revenue (H1, 2026)
          £36.3M
          Gross profit (H1, 2026)
          £22.0M
          Net income (H1, 2026)
          (£19.9M)
          Cash (H1, 2026)
          £10.1M
          EBIT (H1, 2026)
          (£15.5M)
          Enterprise value
          $269.3M

          Footer menu